A-Mansia Biotech S.A., a Louvain-la-Neuve, Belgium-based microbiome company, secured €13m in funding.
The round was led by Seventure Partners with participation from Seventure Partners, Fonds Vives II (University of Louvain, UCL), the SRIW Life Sciences and Nivelinvest, as well as private investor Mr Pierre Drion. A-Mansia has also secured €3m in non-dilutive funding from the Walloon regional government. In conjunction with the funding, Eric de la Fortelle from Seventure Partners will be joining A-Mansia board.
Founded in 2016 and led by Jean-Christophe Malrieu, CEO, A-Mansia Biotech is a microbiome company focused on developing products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium.
The company’s products are based on discoveries made by the founding scientists, Professor Willem M. de Vos from Wageningen University (The Netherlands) and Professor Patrice D. Cani from the University of Louvain (UCL, Belgium).
Isolated in 2004 at Wageningen University, A. muciniphila is one of the most abundant species found in the gut microbiota, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering the intestinal epithelium, which allows the bacterium to establish a close cross-talk with the host. Thanks to these interactions with the host immune and metabolic functions, A. muciniphila acts as the gatekeeper of the intestinal barrier.
The company will use the funds to progress the development of a proprietary nutritional supplement based on A. muciniphila through to commercial launch amd to develop a pharmaceutical research pipeline based on active components isolated from A. muciniphila.